Erratum to "First-line ribociclib plus letrozole for postmenopausal women with HR+, HER2- ABC: MONALEESA-2 safety results" [Breast 36 (Suppl. 1) (November 2017) S44-S45]
Breast
.
2018 Aug:40:53.
doi: 10.1016/j.breast.2018.04.007.
Authors
Wolfgang Janni
1
,
Arlene Chan
2
,
Arnd Nusch
3
,
Emilio Alba
4
,
Thomas Bachelot
5
,
Miguel Gil-Gil
6
,
Joseph Kattan
7
,
Hugues Bourgeois
8
,
Fadi El Karak
9
,
Santosh Sutradhar
10
,
Michelle Miller
10
,
David Chandiwana
10
,
Pierfranco Conte
11
Affiliations
1
Universitätsklinikum Ulm, Department of Oncology, Ulm, Germany. Electronic address: Wolfgang.Janni@uniklinik-ulm.de.
2
Curtin University, Breast Cancer Research Centre WA, Perth, Australia.
3
Onkologische Praxis, Oncology, Velbert, Germany.
4
Hospital Universitario Virgen de la Victoria, Oncology, Málaga, Spain.
5
Centre Léon Bérard, Oncology, Lyon, France.
6
L'Hospitalet de Llobregat, Institut Català d'Oncologia, Barcelona, Spain.
7
Hôtel Dieu de France Hospital, Oncology, Beirut, Lebanon.
8
Centre Jean Bernard, Oncology, Le Mans, France.
9
Bellevue Medical Center, Oncology, Mansourieh, Lebanon.
10
Novartis Pharmaceuticals Corporation, Oncology, East Hanover, NJ, USA.
11
University of Padua, Istituto Oncologico Veneto, IRCCS, Padua, Italy.
PMID:
30005916
DOI:
10.1016/j.breast.2018.04.007
No abstract available
Publication types
Published Erratum